People · Operator
Named in public records as an officer, director or promoter · active 2025–2026 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cognito Therapeutics Group, Inc. | — | Pharma | Series D+ | $196.3M | $1.7B | 2025 |
| Nula Therapeutics, Inc. | — | Biotechnology | Series A | $7.4M | $17.7M | 2026 |
Jarod Rutledge at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jarod Rutledge on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 1 | 13 |
| Stephen Bruso | 1 | 9 |
| Helen Liang | 1 | 4 |
| Richard Kuntz | 1 | 4 |
| Laura Brege | 1 | 3 |
| Nils Regge | 1 | 1 |
| Christopher Shepard | 1 | 1 |
| Christian Howell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.